Clinical Trials Browser

Completed × Breast Neoplasms × Capecitabine × Clear all

NCT05064085 2026-04-06

Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer

Phase 1 Completed

Breast Neoplasms

NCT02767661 2026-02-27

MECCA

Phase 3 Completed

Breast Neoplasms

NCT03523585 2026-02-27

DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

Phase 3 Completed

608 enrolled 17 charts

Breast Neoplasms

NCT01494662 2026-01-23

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

Phase 2 Completed

140 enrolled 32 charts

Breast Neoplasms

NCT06961331 2026-01-09

Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.

Breast Neoplasms

NCT02514681 2025-09-10

PRECIOUS

Phase 3 Completed

Breast Neoplasms

NCT01354522 2025-06-15

TAC Versus TCX as Adjuvant Treatment for High-risk Her2-Negative Breast Cancer

Phase 3 Completed

Breast Neoplasms

NCT03997968 2024-12-24

A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

Phase 1/2 Completed

BreastGastrointestinalGynecologicHead & NeckLymphoidPlasma cellSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Head and Neck Neoplasms, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Lymphoma, Mantle-Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04276493 2024-12-06

Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab

Phase 1/2 Completed

BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms

NCT02892123 2024-11-27

Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers

Phase 1 Completed

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

NCT02009449 2024-11-15

IVY

Phase 1 Completed

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT03901339 2024-10-21

TROPiCS-02

Phase 3 Completed

543 enrolled 25 charts 2 FDA

Breast Neoplasms

NCT03839823 2024-10-09

RIGHT Choice

Phase 2 Completed

222 enrolled 17 charts

Breast Neoplasms

NCT03355157 2024-10-01

PADMA

Phase 4 Completed

Breast Neoplasms, Patient Acceptance of Health Care

NCT02028507 2024-09-25

PEARL

Phase 3 Completed

693 enrolled 40 charts

Breast Neoplasms

NCT03887130 2024-04-30

Study of Oral Vinorelbine Plus Capecitabine Versus Taxane-gemcitabine Combinations as 1st Line Chemotherapy in Metastatic Breast Cancer

Phase 2 Completed

152 enrolled 14 charts

Breast Neoplasms

NCT02954055 2024-02-26

METEORA-II

Phase 2 Completed

140 enrolled 11 charts

Breast Neoplasms, Neoplasm Metastasis

NCT01387295 2023-12-11

Intra-hepatic Chemotherapy in Patients With Liver Metastases From Breast Cancer and Limited Extrahepatic Disease

Phase 2 Completed

38 enrolled 11 charts

Breast Neoplasms

NCT02754011 2023-12-07

GEP14-LEECAP

Phase 1 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT01300962 2023-12-04

Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer

Phase 1 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT03262935 2023-10-19

TULIP

Phase 3 Completed

437 enrolled 17 charts

Breast Neoplasms

NCT02614794 2023-08-14

HER2CLIMB

Phase 2 Completed

612 enrolled 30 charts 3 FDA

Brain Neoplasms, Breast Neoplasms

NCT01439282 2023-06-22

Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer

Phase 2 Completed

77 enrolled 9 charts

Breast Neoplasms

NCT03084939 2023-05-06

Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer

Phase 3 Completed

Breast Neoplasms

NCT00129935 2023-03-31

EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer

Phase 3 Completed

1,384 enrolled 22 charts

Breast Neoplasms

NCT00130533 2023-03-31

Maintenance Treatment With Capecitabine Versus Observation in Breast Cancer Patients

Phase 3 Completed

876 enrolled 24 charts

Breast Neoplasms

NCT04366713 2023-02-10

A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib

Phase 2 Completed

6 enrolled 8 charts

Breast Neoplasms

NCT03462251 2023-01-19

RIBBIT

Phase 3 Completed

Breast Neoplasms

NCT05052437 2023-01-10

PK and Drug Interaction Study of Utidelone Plus Capecitabine in Patients With Advanced Breast Cancer

Phase 1 Completed

Breast Neoplasms

NCT00433589 2022-11-17

MINDACT

Phase 3 Completed

Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Lobular

NCT00807859 2022-11-08

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Phase 1 Completed

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT03473639 2022-11-01

Breast49

Phase 1 Completed

Breast Neoplasms

NCT02574455 2022-06-15

ASCENT

Phase 3 Completed

529 enrolled 23 charts 2 FDA

Breast Neoplasms

NCT01498458 2022-06-10

PazoX

Phase 1 Completed

9 enrolled 15 charts

Breast Neoplasms

NCT01095003 2022-04-28

Trial of Vinflunine Plus Capecitabine in Advanced Breast Cancer

Phase 3 Completed

770 enrolled 13 charts

Breast Neoplasms

NCT02000882 2022-02-07

STAR Cape+BKM120 MBC With Brain Met

Phase 2 Completed

10 enrolled 11 charts

Brain Neoplasms, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01802970 2021-10-08

Safety and Blood Immune Cell Study of Anakinra Plus Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients

Phase 1 Completed

Breast Neoplasms

NCT00365417 2021-04-13

Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer

Phase 2 Completed

45 enrolled 15 charts

Breast Neoplasms

NCT01783444 2021-02-26

BOLERO-6

Phase 2 Completed

309 enrolled 19 charts

Breast Neoplasms, Neoplasm Metastasis

NCT02650752 2021-01-26

Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases

Phase 1 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT01323530 2021-01-11

A Confirmation Study of Eribulin in Combination With Capecitabine

Phase 1/2 Completed

76 enrolled 24 charts

Breast Neoplasms

NCT01471847 2020-12-09

A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab

Phase 1 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT00080301 2020-11-02

Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer

Phase 3 Completed

752 enrolled 22 charts

Breast Neoplasms, Neoplasm Metastasis

NCT00082433 2020-11-02

Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer

Phase 3 Completed

1,221 enrolled 18 charts

Breast Neoplasms, Neoplasms

NCT01387373 2020-10-05

Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Breast Cancer

Phase 2 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT00562718 2020-08-21

Capecitabine and Radiation Therapy in Treating Patients With Nonmetastatic Breast Cancer After Surgery

Phase 2 Completed

50 enrolled 10 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT01950182 2020-07-15

SYSUCC-002

Phase 3 Completed

Breast Neoplasms

NCT00337103 2020-06-18

E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes

Phase 3 Completed

1,276 enrolled 22 charts

Breast Neoplasms

NCT02025192 2020-06-04

A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer

Phase 1 Completed

Breast Neoplasms

NCT01112826 2020-05-27

SYSUCC-001

Phase 3 Completed

Breast Neoplasms, Triple Negative Breast Neoplasms